BioTheranostics
Hologic Fiscal Q3 Revenues Beat Estimates on Rising Non-COVID Sales
The firm posted double-digit growth in non-COVID-19 molecular diagnostics revenues and continues working to bring its Mobidiag products to the US market.
Hologic Reports Gains in Non-COVID Diagnostics, Surgical Products
Company beats its Q3 earnings guidance on strength of women's health diagnostics income, and CEO Steve MacMillan predicted relief from chip supply problems
Hologic Preliminary Fiscal Q1 Revenues Drop 9 Percent
The firm expects fiscal Q1 Diagnostics revenues of $950.4 million, down 16 percent compared to the prior-year quarter when its COVID-19 revenues surged.
Medicare Expands Coverage for Hologic's Biotheranostics Breast Cancer Test
The firm said that the expanded coverage provides more women with access to a test that helps determine whether extended endocrine therapy is appropriate.
The company has invested revenues from its pandemic testing business to buy assets that are growing faster than its base business.
Jun 13, 2019